204 related articles for article (PubMed ID: 24393954)
1. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Takeda Y; Nakahira S; Katsura Y; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Suzuki R; Taniguchi H; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1884-6. PubMed ID: 24393954
[TBL] [Abstract][Full Text] [Related]
2. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
[TBL] [Abstract][Full Text] [Related]
3. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
5. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
[TBL] [Abstract][Full Text] [Related]
8. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Feliu J; Borrega P; León A; López-Gómez L; López M; Castro J; Belda-Iniesta C; Barriuso J; Martínez V; González-Barón M
Cancer Chemother Pharmacol; 2011 Jan; 67(1):215-21. PubMed ID: 20927525
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
11. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Ardavanis A; Kountourakis P; Karagiannis A; Doufexis D; Tzovaras AA; Rigatos G
Anticancer Res; 2009 Dec; 29(12):5211-7. PubMed ID: 20044638
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients.
Grigorescu AC; Bala C
J BUON; 2013; 18(1):188-94. PubMed ID: 23613405
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
16. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
[TBL] [Abstract][Full Text] [Related]
17. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
19. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Konski A; Meyer JE; Joiner M; Hall MJ; Philip P; Shields A; McSpadden E; Choi M; Adaire B; Duncan G; Meropol NJ; Cescon TP; Cohen SJ
Radiother Oncol; 2014 Oct; 113(1):35-40. PubMed ID: 25441058
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]